MCID: OBS002
MIFTS: 66

Obsessive-Compulsive Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Disorder

MalaCards integrated aliases for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 57 12 37 29 55 43 44 15 63 73
Obsessive-Compulsive Disorder, Susceptibility to 57 6
Obsessive Compulsive Disorder 12 40
Ocd 57 76
Obsessive Compulsive Behavior 73
Anancastic Neurosis 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant form


HPO:

32
obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 164230
Disease Ontology 12 DOID:10933
ICD10 33 F42
ICD9CM 35 300.3
MeSH 44 D009771
NCIt 50 C88411
MedGen 42 C0028768
KEGG 37 H01450
SNOMED-CT via HPO 69 263681008 12479006

Summaries for Obsessive-Compulsive Disorder

MedlinePlus : 43 Obsessive-compulsive disorder (OCD) is a type of anxiety disorder. If you have OCD, you have frequent, upsetting thoughts called obsessions. To try to control the thoughts, you feel an overwhelming urge to repeat certain rituals or behaviors. These are called compulsions. Examples of obsessions are a fear of germs or a fear of being hurt. Compulsions include washing your hands, counting, checking on things, or cleaning. With OCD, the thoughts and rituals cause distress and get in the way of your daily life. Researchers think brain circuits may not work properly in people who have OCD. It tends to run in families. The symptoms often begin in children or teens. Treatments include therapy, medicines, or both. One type of therapy, cognitive behavioral therapy, is useful for treating OCD. NIH: National Institute of Mental Health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as obsessive-compulsive disorder, susceptibility to, is related to autism spectrum disorder and trichotillomania, and has symptoms including sleep disturbances, photophobia and psychiatric symptom. An important gene associated with Obsessive-Compulsive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Serotonergic synapse and Dopaminergic synapse. The drugs Citalopram and Fluvoxamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are obsessive-compulsive behavior and Decreased viability

OMIM : 57 Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002). Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999). (164230)

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

PubMed Health : 63 About obsessive-compulsive disorder: We all know the worrying feeling that we have forgotten to do something, like turning off the oven or locking the door. And it might be a good idea to double-check if you aren't absolutely sure. But some people are so worried about forgetting to do something that they feel the urge to check over and over again. Compulsive urges like this may gradually come to dominate their whole life. There are different types of obsessive-compulsive disorder (OCD). Some people are so afraid of germs that they constantly wash their hands. Others can't stop counting things, cleaning their surroundings or obsessing over the same repetitive thoughts. Regardless of the kind of ritual they may have developed, people who have OCD just can't stop doing these things.

Wikipedia : 76 Obsessive–compulsive disorder (OCD) is a mental disorder where people feel the need to check things... more...

Related Diseases for Obsessive-Compulsive Disorder

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 33.1 BDNF HTR2A OXT SLC6A4
2 trichotillomania 32.2 DLGAP3 SLITRK1
3 agoraphobia 31.8 HTR1A MAOA SLC6A4
4 gilles de la tourette syndrome 31.8 BDNF COMT DRD2 DRD4 HTR3A SGCE
5 anorexia nervosa 31.5 BDNF COMT HTR2A OXT SLC6A4
6 dysthymic disorder 31.5 HTR2A MAOA SLC6A4
7 alexithymia 31.4 COMT DRD2 HTR1A SLC6A4
8 brain injury 31.3 BDNF COMT DRD2
9 asperger syndrome 31.2 OXT SGCE SLC6A4
10 traumatic brain injury 31.1 BDNF COMT DRD2
11 kleptomania 31.1 HTR1A MAOA SLC6A4 SLITRK1
12 phobia, specific 31.1 COMT MAOA
13 pathological gambling 31.0 DRD2 DRD4 HTR2A MAOA SLC6A3 SLC6A4
14 drug dependence 31.0 BDNF DRD2 SLC6A4
15 movement disease 31.0 DRD2 SGCE SLC6A3
16 social phobia 31.0 DRD2 HTR1A HTR3A MAOA SLC6A4
17 separation anxiety disorder 31.0 DRD4 OXT SLC6A3
18 pervasive developmental disorder 31.0 BDNF OXT SLC6A4
19 tic disorder 30.9 DRD2 DRD4 HTR2A SLC6A3 SLITRK1 TPH2
20 schizoaffective disorder 30.8 BDNF COMT DRD2 HTR2A SLC1A1 SLC6A4
21 eating disorder 30.8 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
22 temporal lobe epilepsy 30.8 BDNF HTR1A SLC1A1
23 post-traumatic stress disorder 30.6 BDNF COMT DRD2 HTR2A MAOA SLC6A4
24 bipolar i disorder 30.6 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
25 impulse control disorder 30.6 DLGAP3 DRD2 DRD4 SLITRK1
26 bulimia nervosa 30.4 BDNF COMT HTR1B HTR2A HTR3A MAOA
27 anxiety 30.4 BDNF COMT HTR1A HTR2A HTR2C HTR3A
28 paranoid schizophrenia 30.3 BDNF COMT HTR2A MAOA SLC6A4 TPH2
29 narcolepsy 30.2 COMT DRD2 HTR2A SLC6A3 TPH1
30 generalized anxiety disorder 30.1 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
31 serotonin syndrome 30.1 HTR1A HTR2A HTR3A MAOA OXT SLC6A4
32 early-onset schizophrenia 29.8 BDNF COMT DRD2 DRD4 HTR2A HTR3A
33 depression 29.8 BDNF HTR1A HTR2A HTR2C HTR3A MAOA
34 panic disorder 29.3 BDNF COMT HTR1A HTR2A HTR2C HTR3A
35 autism 29.1 BDNF COMT DRD2 DRD4 HTR1A HTR2A
36 personality disorder 28.5 BDNF COMT DRD2 DRD4 HTR1A HTR1B
37 mood disorder 28.2 BDNF COMT DRD2 DRD4 HTR1A HTR1B
38 psychotic disorder 28.0 BDNF COMT DRD2 DRD4 HTR1A HTR2A
39 bipolar disorder 28.0 BDNF COMT DRD2 DRD4 HTR1A HTR2A
40 attention deficit-hyperactivity disorder 27.8 BDNF COMT DRD2 DRD4 HTR1A HTR1B
41 schizophrenia 27.7 BDNF COMT DRD2 DRD4 HTR1A HTR1B
42 major depressive disorder 27.1 BDNF COMT DRD2 DRD4 HTR1A HTR1B
43 alcohol dependence 27.1 BDNF COMT DRD2 DRD4 HTR1A HTR1B
44 osteochondritis dissecans 11.8
45 pandas 11.6
46 pediatric acute-onset neuropsychiatric syndrome 11.4
47 dystonia, dopa-responsive 11.1
48 succinic semialdehyde dehydrogenase deficiency 11.1
49 chromosome 15q11.2 deletion syndrome 11.1
50 mental retardation, autosomal dominant 23 11.1

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Personality Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:



Diseases related to Obsessive-Compulsive Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

Symptoms via clinical synopsis from OMIM:

57
Neuro:
obsessive-compulsive disorder


Clinical features from OMIM:

164230

Human phenotypes related to Obsessive-Compulsive Disorder:

32
# Description HPO Frequency HPO Source Accession
1 obsessive-compulsive behavior 32 HP:0000722

UMLS symptoms related to Obsessive-Compulsive Disorder:


sleep disturbances, photophobia, psychiatric symptom, mental and behavioral signs and symptoms, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 SLC6A4 HTR1A HTR3A
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 HTR2C HTR3A MAOA OXT SGCE SLC1A1
2 homeostasis/metabolism MP:0005376 10.2 DRD2 DRD4 HTR1A HTR2C HTR3A MAOA
3 cardiovascular system MP:0005385 10.13 COMT DRD2 HTR1A HTR1B MAOA OXT
4 growth/size/body region MP:0005378 10.11 BDNF DRD2 HTR1B HTR2C HTR3A OXT
5 endocrine/exocrine gland MP:0005379 10.1 BDNF COMT DRD2 HTR1B HTR2A HTR3A
6 adipose tissue MP:0005375 10.02 TPH1 TPH2 DRD2 HTR1B HTR2C OXT
7 integument MP:0010771 9.96 BDNF DLGAP3 DRD2 HTR2C HTR3A OXT
8 nervous system MP:0003631 9.86 BDNF COMT DLGAP3 DRD2 DRD4 HTR1A
9 muscle MP:0005369 9.81 DRD2 HTR1B HTR2A HTR2C HTR3A SGCE
10 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Obsessive-Compulsive Disorder

PubMedHealth treatment related to Obsessive-Compulsive Disorder: 63

Although there's no “cure” for OCD, with good professional help the symptoms can be reduced to a tolerable level, enabling people with OCD to start leading normal lives again.People with OCD are usually advised to have psychological treatment. Cognitive behavioral therapy (CBT) in particular has been proven to be an effective treatment for OCD. In Germany, it is offered by behavioral therapists (in German: Verhaltenstherapeuten).Medication for depression (antidepressants) may be considered in addition to CBT, or if psychological treatment isn't an option (yet). Selective serotonin re-uptake inhibitors (SSRIs) are commonly used for this purpose.Apart from these treatments, self-help is an option, for example by talking to other people with OCD in a support group. Some people like to use books or websites to learn about their obsessive-compulsive behaviors and deal with them. Others may try to manage their OCD using relaxation techniques like meditation or autogenic training.

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
2
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Not Applicable 54739-18-3 3404 5324346
3
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 303-49-1 2801
4
Cycloserine Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-41-7 401 6234
5
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Paroxetine Approved, Investigational Phase 4,Phase 3,Not Applicable 61869-08-7 43815
8
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
9
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
10
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 54910-89-3 3386
12
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79617-96-2 68617
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
15
Methylphenidate Approved, Investigational Phase 4,Phase 2,Not Applicable 113-45-1 4158
16
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
17
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
18
Acamprosate Approved, Investigational Phase 4,Phase 2 77337-76-9 71158
19
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
20
Clonidine Approved Phase 4 4205-90-7 2803
21 Piracetam Approved, Investigational Phase 4,Phase 2,Phase 3 7491-74-9
22
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
23
Propranolol Approved, Investigational Phase 4 525-66-6 4946
24 Etiracetam Investigational Phase 4,Phase 2,Phase 3 33996-58-6
25
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
26 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
32 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Not Applicable
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
44 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Antidepressive Agents, Tricyclic Phase 4,Phase 3,Phase 2,Not Applicable
47 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 439)
# Name Status NCT ID Phase Drugs
1 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
4 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
5 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
6 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
7 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
8 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
9 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
10 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
11 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
12 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
13 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
14 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
15 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
16 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
17 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
18 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
19 Escitalopram in Schizophrenia in OCD- Open Label Study Completed NCT00456937 Phase 4 Escitalopram
20 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
21 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
22 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
23 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
24 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
26 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
27 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
28 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
29 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
30 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
31 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
32 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
33 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
34 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
35 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
36 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
37 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
38 Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Unknown status NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
39 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
40 Comparison of DBS Targets in Obsessive-compulsive Disorder Completed NCT01807403 Phase 3
41 Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders Completed NCT00932204 Phase 3
42 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
43 Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
44 A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder Completed NCT00369642 Phase 3
45 Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed NCT00000384 Phase 3 Sertraline
46 D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD) Completed NCT01411774 Phase 3 d-cycloserine;Pill placebo
47 Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD) Completed NCT00305500 Phase 3 escitalopram
48 Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Completed NCT00533806 Phase 3
49 Treatment of Obsessive Compulsive Disorder in Children Completed NCT00074815 Phase 3 Serotonin reuptake inhibitors management
50 Family Based Treatment of Early Childhood Obsessive Compulsive Disorder Completed NCT00055068 Phase 3

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: obsessive-compulsive disorder

Genetic Tests for Obsessive-Compulsive Disorder

Genetic tests related to Obsessive-Compulsive Disorder:

# Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 29 BDNF HTR2A SLC6A4

Anatomical Context for Obsessive-Compulsive Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

41
Brain, Cortex, Testes, Subthalamic Nucleus, Colon, Skin, Prefrontal Cortex

Publications for Obsessive-Compulsive Disorder

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 1600)
# Title Authors Year
1
Labour market marginalisation in obsessive-compulsive disorder: a nationwide register-based sibling control study. ( 29950186 )
2018
2
Progress and challenges in deep brain stimulation for obsessive-compulsive disorder. ( 29406245 )
2018
3
Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial. ( 29966992 )
2018
4
Obsessive-compulsive symptoms in children with first degree relatives diagnosed with obsessive-compulsive disorder. ( 29898190 )
2018
5
Augmentation Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation Over Presupplementary Motor Area in Obsessive-Compulsive Disorder: A Randomized Controlled Trial. ( 29901496 )
2018
6
Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. ( 29899808 )
2018
7
Subthalamic theta activity: a novel human subcortical biomarker for obsessive compulsive disorder. ( 29915200 )
2018
8
Mindfulness-based cognitive therapy for obsessive-compulsive disorder: Study protocol for a randomized controlled trial with functional magnetic resonance imaging and a 6-month follow-up. ( 29974808 )
2018
9
Significant concordance of genetic variation that increases both the risk for obsessive-compulsive disorder and the volumes of the nucleus accumbens and putamen. ( 29947313 )
2018
10
Treatment-Refractory Obsessive-Compulsive Disorder in Adults: A Cost-Effectiveness Analysis of Treatment Strategies. ( 29419948 )
2018
11
Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York. ( 29937263 )
2018
12
Internet-delivered cognitive behavioural therapy for young children with obsessive-compulsive disorder: development and initial evaluation of the BIP OCD Junior programme. ( 29971153 )
2018
13
The detection of white matter alterations in obsessive-compulsive disorder revealed by TRActs Constrained by UnderLying Anatomy (TRACULA). ( 29950845 )
2018
14
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
15
The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). ( 29930930 )
2018
16
Assessing Acute Secondary Treatment Outcomes in Early-Onset Obsessive-Compulsive Disorder. ( 29435695 )
2018
17
A network perspective on comorbid depression in adolescents with obsessive-compulsive disorder. ( 29125957 )
2018
18
Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence. ( 29908912 )
2018
19
Association between glutamate transporter gene polymorphisms and obsessive-compulsive disorder/trait empathy in a Korean population. ( 29304071 )
2018
20
Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder. ( 29953682 )
2018
21
Suicide risk in Obsessive-Compulsive Disorder and exploration of risk factors: a systematic review. ( 29929465 )
2018
22
Lost in translation? A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies. ( 29275640 )
2018
23
Pituitary gland volumes in patients with obsessive-compulsive disorder before and after cognitive-behavioral therapy. ( 29898196 )
2018
24
Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder. ( 29394511 )
2018
25
8-F2-isoprostane, thioredoxin and thioredoxin reductase levels in children with obsessive-compulsive disorder. ( 29927677 )
2018
26
Eveningness is associated with poor sleep quality and negative affect in obsessive-compulsive disorder. ( 29415552 )
2018
27
Safety of Transcranial Magnetic Stimulation in an Obsessive-Compulsive Disorder Patient With Deep Brain Stimulation: A Case Report. ( 29952858 )
2018
28
The relationship between theory of mind and insight in obsessive-compulsive disorder. ( 29426262 )
2018
29
White Matter Features Associated With Autistic Traits in Obsessive-Compulsive Disorder. ( 29896127 )
2018
30
Obsessive-compulsive disorder after therapy for an optic pathway glioma. ( 29556577 )
2018
31
Increased Default Mode Network Connectivity in Obsessive-Compulsive Disorder During Reward Processing. ( 29951007 )
2018
32
Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. ( 29440404 )
2018
33
The temporal relationship between premonitory urges and covert compulsions in patients with obsessive-compulsive disorder. ( 29407570 )
2018
34
A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD). ( 29423665 )
2018
35
Altered Functional Connectivity of the Default Mode Network in Patients With Schizo-obsessive Comorbidity: A Comparison Between Schizophrenia and Obsessive-compulsive Disorder. ( 29365198 )
2018
36
A Case of Obsessive-Compulsive Disorder Comorbid with Miyoshi Myopathy. ( 29403136 )
2018
37
Changing disgust through imagery rescripting and cognitive reappraisal in contamination-based obsessive-compulsive disorder. ( 29421371 )
2018
38
Sertraline induced cervical dystonia in a patient of Obsessive Compulsive Disorder. ( 29447992 )
2018
39
Presidential Address: Are the Obsessive-Compulsive Related Disorders Related to Obsessive-Compulsive Disorder? A Critical Look at DSM-5's New Category. ( 29405915 )
2018
40
Increased Loss Aversion in Unmedicated Patients with Obsessive-Compulsive Disorder. ( 29379449 )
2017
41
Peripheral SLC6A4 Gene Expression in Obsessive-Compulsive Disorder in the Han Chinese Population. ( 28904509 )
2017
42
Overvalued ideation in adolescents with obsessive-compulsive disorder. ( 28528243 )
2017
43
Tics and obsessive-compulsive disorder in relation to diet: Two case reports. ( 28870689 )
2017
44
Altered serotonergic and GABAergic neurotransmission in a mice model of obsessive-compulsive disorder. ( 28916503 )
2017
45
Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. ( 28903922 )
2017
46
Low intensity interventions for Obsessive-Compulsive Disorder (OCD): a qualitative study of mental health practitioner experiences. ( 28222706 )
2017
47
Separating obsessive-compulsive disorder from the self. A qualitative study of family member perceptions. ( 28882118 )
2017
48
Obsessive-compulsive disorder and family accommodation: A 3-year follow-up. ( 28364587 )
2017
49
Obsessive-compulsive disorder, which genes? Which functions? Which pathways? An integrated holistic view regarding OCD and its complex genetic etiology. ( 28608743 )
2017
50
Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates. ( 28976410 )
2017

Variations for Obsessive-Compulsive Disorder

ClinVar genetic disease variations for Obsessive-Compulsive Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC6A4 NM_001045.5(SLC6A4): c.1273A> G (p.Ile425Val) single nucleotide variant risk factor rs28914832 GRCh37 Chromosome 17, 28538374: 28538374
2 SLC6A4 NM_001045.5(SLC6A4): c.1273A> G (p.Ile425Val) single nucleotide variant risk factor rs28914832 GRCh38 Chromosome 17, 30211356: 30211356
3 HTR2A HTR2A, -1438G-A single nucleotide variant risk factor

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder

Expression for Obsessive-Compulsive Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.

Pathways for Obsessive-Compulsive Disorder

Pathways related to Obsessive-Compulsive Disorder according to KEGG:

37
# Name Kegg Source Accession
1 Serotonergic synapse hsa04726
2 Dopaminergic synapse hsa04728
3 Glutamatergic synapse hsa04724

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 COMT DRD2 DRD4 MAOA SLC1A1 SLC6A3
2
Show member pathways
12.83 COMT DLGAP3 MAOA SLC1A1 SLC6A3 SLC6A4
3 12.41 COMT HTR1A SLC1A1 TPH1 TPH2
4
Show member pathways
12.13 BDNF DRD2 HTR1A HTR1B
6 11.97 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
7
Show member pathways
11.84 HTR1A HTR1B HTR3A
8
Show member pathways
11.83 BDNF DRD2 MAOA SLC6A3
9
Show member pathways
11.79 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
10 11.66 DRD2 HTR2A HTR2C
11 11.66 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
12
Show member pathways
11.3 MAOA SLC6A3 SLC6A4 TPH2
13
Show member pathways
11.04 COMT MAOA SLC6A3 SLC6A4
14
Show member pathways
10.95 COMT MAOA TPH1
15 10.87 HTR2A HTR2C
16
Show member pathways
10.73 COMT MAOA
17 10.72 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
18 10.69 COMT MAOA

GO Terms for Obsessive-Compulsive Disorder

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.77 HTR3A SLC6A3 SLC6A4 TPH1 TPH2
2 integral component of plasma membrane GO:0005887 9.7 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
3 axon GO:0030424 9.63 BDNF COMT DRD2 HTR2A HTR3A SLC6A3
4 dendrite GO:0030425 9.23 BDNF COMT DRD2 HTR1A HTR1B HTR2A
5 membrane GO:0016020 10.28 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B
6 integral component of membrane GO:0016021 10.17 COMT DRD2 DRD4 HTR1A HTR1B HTR2A
7 plasma membrane GO:0005886 10.1 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.89 DRD4 HTR2A HTR2C
2 response to ethanol GO:0045471 9.89 DRD2 HTR1B HTR3A SLC6A3
3 locomotory behavior GO:0007626 9.88 DRD2 HTR2C SLC6A3
4 circadian rhythm GO:0007623 9.87 SLC6A4 TPH1 TPH2
5 synapse assembly GO:0007416 9.85 BDNF DRD2 SLITRK1
6 chemical synaptic transmission GO:0007268 9.85 HTR1A HTR1B HTR2A HTR2C HTR3A SLC1A1
7 positive regulation of synapse assembly GO:0051965 9.84 BDNF OXT SLITRK1
8 positive regulation of fat cell differentiation GO:0045600 9.82 HTR2A HTR2C TPH1
9 social behavior GO:0035176 9.82 DRD4 OXT SLC6A4
10 feeding behavior GO:0007631 9.81 DRD2 HTR1B HTR2C
11 memory GO:0007613 9.81 BDNF HTR2A OXT SLC6A4
12 release of sequestered calcium ion into cytosol GO:0051209 9.79 DRD2 HTR2A HTR2C
13 behavioral fear response GO:0001662 9.76 DRD4 HTR1A HTR2C
14 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.76 HTR1A HTR1B HTR2A HTR2C
15 response to amphetamine GO:0001975 9.75 DRD2 DRD4 OXT
16 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.73 HTR1A HTR1B HTR2A
17 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD4
18 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
19 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD4
20 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
21 behavioral response to cocaine GO:0048148 9.72 DRD2 DRD4 HTR2A
22 bone remodeling GO:0046849 9.71 HTR1B TPH1
23 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 OXT
24 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 DRD4
26 grooming behavior GO:0007625 9.71 DRD2 OXT
27 regulation of dopamine secretion GO:0014059 9.71 DRD2 HTR1B HTR2A
28 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
29 G-protein coupled receptor internalization GO:0002031 9.7 DRD2 HTR1B
30 vasoconstriction GO:0042310 9.7 HTR1A HTR1B SLC6A4
31 response to drug GO:0042493 9.7 COMT DRD2 HTR1B HTR2A HTR2C SLC6A3
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD2 DRD4
33 sleep GO:0030431 9.69 HTR2A OXT
34 neurotransmitter catabolic process GO:0042135 9.69 COMT MAOA
35 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
36 aromatic amino acid family metabolic process GO:0009072 9.68 TPH1 TPH2
37 monoamine transport GO:0015844 9.68 SLC6A3 SLC6A4
38 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
39 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR1B HTR2A
40 drinking behavior GO:0042756 9.66 HTR1B OXT
41 regulation of hormone secretion GO:0046883 9.66 HTR1A HTR2A
42 dopamine uptake involved in synaptic transmission GO:0051583 9.65 SLC6A3 SLC6A4
43 sperm ejaculation GO:0042713 9.65 OXT SLC6A4
44 dopamine metabolic process GO:0042417 9.65 COMT DRD2 DRD4
45 indolalkylamine biosynthetic process GO:0046219 9.64 TPH1 TPH2
46 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.63 HTR1A HTR1B
47 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.62 HTR2A HTR2C
48 serotonin biosynthetic process GO:0042427 9.61 TPH1 TPH2
49 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD2 DRD4
50 regulation of behavior GO:0050795 9.61 HTR1A HTR1B HTR2A

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.85 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
2 symporter activity GO:0015293 9.73 SLC1A1 SLC6A3 SLC6A4
3 neurotransmitter receptor activity GO:0030594 9.56 HTR1A HTR1B HTR2A HTR2C
4 neurotransmitter:sodium symporter activity GO:0005328 9.55 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD2 DRD4
6 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A3 SLC6A4
7 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
8 dopamine neurotransmitter receptor activity GO:0004952 9.49 DRD2 DRD4
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.48 TPH1 TPH2
10 dopamine:sodium symporter activity GO:0005330 9.46 SLC6A3 SLC6A4
11 G-protein coupled serotonin receptor activity GO:0004993 9.46 HTR1A HTR1B HTR2A HTR2C
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.43 HTR2A HTR2C
13 drug binding GO:0008144 9.43 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
14 tryptophan 5-monooxygenase activity GO:0004510 9.4 TPH1 TPH2
15 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C HTR3A
16 G-protein coupled receptor activity GO:0004930 10.01 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C

Sources for Obsessive-Compulsive Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....